Immunosuppressive serum factors and lymphocyte deficiency in Hodgkin's disease. 1979

G Holm, and B Angelin, and M Björkholm, and P Ericsson, and H Mellstedt, and D Pettersson

UI MeSH Term Description Entries
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008231 Lymphopenia Reduction in the number of lymphocytes. Lymphocytopenia,Lymphocytopenias,Lymphopenias
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003208 Concanavalin A A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D006689 Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. Granuloma, Hodgkin,Granuloma, Malignant,Hodgkin Lymphoma,Lymphogranuloma, Malignant,Granuloma, Hodgkin's,Granuloma, Hodgkins,Hodgkin Lymphoma, Adult,Hodgkin's Disease,Hodgkin's Lymphoma,Hodgkins Disease,Lymphocyte Depletion Hodgkin's Lymphoma,Lymphocyte-Rich Classical Hodgkin's Lymphoma,Mixed Cellularity Hodgkin's Lymphoma,Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,Nodular Sclerosing Hodgkin's Lymphoma,Adult Hodgkin Lymphoma,Disease, Hodgkin,Disease, Hodgkin's,Disease, Hodgkins,Hodgkin Granuloma,Hodgkin's Granuloma,Hodgkins Granuloma,Hodgkins Lymphoma,Lymphocyte Rich Classical Hodgkin's Lymphoma,Lymphogranulomas, Malignant,Lymphoma, Hodgkin,Lymphoma, Hodgkin's,Malignant Granuloma,Malignant Granulomas,Malignant Lymphogranuloma,Malignant Lymphogranulomas,Nodular Lymphocyte Predominant Hodgkin's Lymphoma
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

G Holm, and B Angelin, and M Björkholm, and P Ericsson, and H Mellstedt, and D Pettersson
November 1982, Cancer,
G Holm, and B Angelin, and M Björkholm, and P Ericsson, and H Mellstedt, and D Pettersson
May 1973, National Cancer Institute monograph,
G Holm, and B Angelin, and M Björkholm, and P Ericsson, and H Mellstedt, and D Pettersson
January 1983, Progress in clinical and biological research,
G Holm, and B Angelin, and M Björkholm, and P Ericsson, and H Mellstedt, and D Pettersson
July 1977, Bollettino dell'Istituto sieroterapico milanese,
G Holm, and B Angelin, and M Björkholm, and P Ericsson, and H Mellstedt, and D Pettersson
March 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
G Holm, and B Angelin, and M Björkholm, and P Ericsson, and H Mellstedt, and D Pettersson
March 1977, The New England journal of medicine,
G Holm, and B Angelin, and M Björkholm, and P Ericsson, and H Mellstedt, and D Pettersson
December 1999, British journal of cancer,
G Holm, and B Angelin, and M Björkholm, and P Ericsson, and H Mellstedt, and D Pettersson
January 1986, Cancer investigation,
G Holm, and B Angelin, and M Björkholm, and P Ericsson, and H Mellstedt, and D Pettersson
March 1976, Lymphology,
G Holm, and B Angelin, and M Björkholm, and P Ericsson, and H Mellstedt, and D Pettersson
January 1972, Vutreshni bolesti,
Copied contents to your clipboard!